Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab Dose-Exploration in IV Steroid-Refractory Ulcerative Colitis
NCT00307827Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Apr 2006
- Primary completion
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of visilizumab in ulcerative colitis (UC) (3 arms), sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects who respond to treatment at Day 45. Started Apr 2006; status: terminated.
02
Drugs
visilizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00307827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307827.